These properties of trafficking to the TME, recognition of tumor-associated ligands with multiple endogenous activating NK cell receptors, and retention of cytotoxic function likely explain the intriguing results of improved overall survival obtained in the randomized trial of patients with advanced NSCLC who received anti-PD-1 mAb therapy with infusions of freshly activated unmatched NK cells (i.e., no cryopreservation), compared with those who received only anti-PD-1 mAb (22). Here, PDCD1 is linked to non-small cell lung carcinoma.